Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

<p>Raw log2LFQ values for kinases profiled by MIB/MS</p>

Guardado en:

Detalles Bibliográficos
Autor principal:	Alyssa C. Flint (16676029) (author)
Otros Autores:	Dana K. Mitchell (16676032) (author), Steven P. Angus (15084264) (author), Abbi E. Smith (16676035) (author), Waylan Bessler (16676038) (author), Li Jiang (16676041) (author), Henry Mang (15293185) (author), Xiaohong Li (16676044) (author), Qingbo Lu (16676047) (author), Brooke Rodriguez (16676050) (author), George E. Sandusky (16676053) (author), Andi R. Masters (16676056) (author), Chi Zhang (15084270) (author), Pengtao Dang (16676059) (author), Jenna Koenig (16676062) (author), Gary L. Johnson (15081520) (author), Weihua Shen (16676065) (author), Jiangang Liu (15018711) (author), Amit Aggarwal (16610489) (author), Gregory P. Donoho (16676068) (author), Melinda D. Willard (16676071) (author), Shripad V. Bhagwat (16676074) (author), D. Wade Clapp (16676077) (author), Steven D. Rhodes (16676080) (author)
Publicado:	2025
Materias:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Cycle CDKs and CDK inhibitors Chemotherapy Combination chemotherapy Gene Technologies High-throughput sequencing Preclinical Models Animal models of cancer Proteomics Rare Cancers Translational Research
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares